Premium
Anemia and neutrophil‐to‐lymphocyte ratio in laryngeal cancer treated with induction chemotherapy
Author(s) -
Gorphe Philippe,
Bouhir Samia,
Garcia Gabriel C. T. E.,
Alali Abeer,
Even Caroline,
Breuskin Ingrid,
Tao Yungan,
Janot François,
Bidault François,
Temam Stéphane
Publication year - 2020
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.28021
Subject(s) - medicine , chemotherapy , anemia , neutrophil to lymphocyte ratio , gastroenterology , cancer , hemoglobin , induction chemotherapy , oncology , retrospective cohort study , single center , lymphocyte , surgery
Objectives/Hypothesis We studied the influence of the neutrophil‐to‐lymphocyte ratio (NLR) and anemia on the response to induction chemotherapy (IC) and survival outcomes in laryngeal cancer patients treated with a preservation protocol. Study Design Retrospective single‐center case series. Methods We analyzed patients with T3 laryngeal cancer treated with IC using a preservation protocol. The NLR and hemoglobin levels were assessed before treatment and after IC. The response to chemotherapy was assessed using Response Evaluation Criteria in Solid Tumours 1.1 and World Heath Organization standards. The oncological endpoints were overall survival (OS) and disease‐free survival (DFS). Results Sixty‐eight patients were analyzed. The median NLR and hemoglobin levels before and after IC were 2.76 and 14.5 g/dL, and 2.01 and 11.6 g/dL, respectively. The NLR and anemia before treatment were not correlated, and they were not associated with the response to chemotherapy. However, an NLR > 5 and anemia before treatment were both associated with shorter OS and DFS. Notably, they were the only factors found to be significantly associated with survival outcomes. Conclusions In laryngeal cancer, patients treated with a preservation protocol, a high NLR ratio, and anemia before IC were associated with shorter survival, independently of the response to chemotherapy. Level of Evidence 4 Laryngoscope , 130:E144–E150, 2020